Bioresorbable Everolimus-Eluting Vascular Scaffold for Patients With Peripheral Artery Disease (ESPRIT I): 2-Year Clinical and Imaging Results
Johannes Lammer, Marc Bosiers, Koen Deloose, Andrej Schmidt, Thomas Zeller, Florian Wolf, Wouter Lansink, Antoine Sauguet, Frank Vermassen, Geert Lauwers, Dierk Scheinert, Jeffrey J Popma, Robert McGreevy, Richard Rapoza, Lewis B Schwartz, Michael R Jaff, Johannes Lammer, Marc Bosiers, Koen Deloose, Andrej Schmidt, Thomas Zeller, Florian Wolf, Wouter Lansink, Antoine Sauguet, Frank Vermassen, Geert Lauwers, Dierk Scheinert, Jeffrey J Popma, Robert McGreevy, Richard Rapoza, Lewis B Schwartz, Michael R Jaff
Abstract
Objectives: This is the first-in-human study of a drug-eluting bioresorbable vascular scaffold (BVS) for treatment of peripheral artery disease (PAD) involving the external iliac artery (EIA) and superficial femoral artery (SFA).
Background: Drug-eluting BVS has shown promise in coronary arteries.
Methods: The ESPRIT BVS system is a device-drug combination consisting of an everolimus-eluting poly-l-lactide scaffold. Safety and performance were evaluated in 35 subjects with symptomatic claudication.
Results: Lesions were located in the SFA (88.6%) and EIA (11.4%). Mean lesion length was 35.7 ± 16.0 mm. The study device was successfully deployed in 100% of cases, without recoil. Procedure-related minor complications were observed in 3 patients (groin hematoma, dissection). Within 2 years there was 1 unrelated death, but no patients in this cohort had an amputation. At 1 and 2 years, the binary restenosis rates were 12.1% and 16.1%, respectively, and target lesion revascularization was performed in 3 of 34 patients (8.8%) and 4 of 32 patients (11.8%), respectively. The ankle brachial index 0.75 ± 0.14 improved from pre-procedure to 0.96 ± 0.16 at 2 years' follow-up. At 2 years, 71.0% of the patients were Rutherford-Becker 0, and 93.5% achieved a maximum walking distance of 1,500 feet.
Conclusions: The safety of the ESPRIT BVS was demonstrated with no procedure or device-related deaths or amputations within 2 years. The low occurrence of revascularizations was consistent with duplex-ultrasonography showing sustained patency at 2-years. (A Clinical Evaluation of the Abbott Vascular ESPRIT BVS [Bioresorbable Vascular Scaffold] System [ESPRIT I]; NCT01468974).
Keywords: bioresorbable vascular scaffold; drug-eluting stent(s); femoropopliteal artery; peripheral artery disease; poly-l-lactide.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Source: PubMed